France Fines Novo Nordisk, Eli Lilly Over Illegal Drug Advertisements

France's national drug safety agency, ANSM, has imposed significant fines on pharmaceutical giants Novo Nordisk and Eli Lilly for violating regulations concerning the advertising of prescription medications. The core issue lies in the illegal promotion of drugs requiring a doctor's prescription, which is strictly prohibited under French law. This action underscores France's commitment to regulating pharmaceutical marketing and preventing direct-to-consumer advertising of potent medications.

“

According to French law, it is forbidden to advertise drugs that require a doctor's prescription.

Novo Nordisk was hit with the largest penalty, amounting to €1.78 million (approximately 250 million Icelandic króna). This fine was divided between its obesity drugs Saxenda and Wegovy. Eli Lilly also faced penalties, with a €108,000 fine for its drug Mounjaro. The agency deemed the advertisements likely to mislead the public and potentially encourage the use of prescription treatments for obesity without proper medical consultation.

“

The agency fined Novo Nordisk €1.78 million or about 250 million Icelandic króna.

Both companies are reportedly considering appeals against the fines. The ANSM's stance is clear: it aims to prevent any communication that might encourage the use of medication as a primary response to obesity, urging the public to consult healthcare professionals. This regulatory action reflects a broader concern in France, where approximately 18% of the population struggles with obesity, highlighting the delicate balance between addressing a public health issue and maintaining stringent controls on pharmaceutical advertising.

“

The French Medicines Agency considered the companies' advertisements likely to mislead the public.